Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2008 Jan 31;35(2):375–382. doi: 10.1007/s00726-007-0611-3

Cleavage mechanism of the H5N1 hemagglutinin by trypsin and furin

X-L Guo 1, L Li 1, D-Q Wei 1,2, Y-S Zhu 1, K-C Chou 2
PMCID: PMC7088033  PMID: 18235997

Summary.

The cleavage property of hemagglutinin (HA) by different proteases was the prime determinant for influenza A virus pathogenicity. In order to understand the cleavage mechanism, molecular modeling tools were utilized to study the coupled model systems of the proteases, i.e., trypsin and furin and peptides of the cleavage sites specific to H5N1 and H1 HAs, which constitute models of HA precursor in complex with cleavage proteases. The peptide segments ‘RERRRKKR ↓ G’ and ‘SIQSR ↓ G’ from the high pathogenic H5N1 H5 and the low pathogenic H1N1 H1 cleavage sites were docking to the trypsin and furin active pockets, respectively. It was observed through the docking studies that trypsin was able to recognize and cleave both the high pathogenic and low pathogenic hemagglutinin, while furin could only cleave the high pathogenic hemagglutinin. An analysis of binding energies indicated that furin got most of its selectivity due to the interactions with P1, P4, and P6, while having less interaction with P2 and little interactions with P3, P5, P7, and P8. Some mutations of H5N1 H5 cleavage sequence fitted less well into furin and would reduce high pathogenicity of the virus. These findings hint that we should focus at the subsites P1, P4, and P6 for developing drugs against H5N1 viruses.

Keywords: Keywords: Trypsin – Furin – H5N1 hemagglutinin – Cleavage mechanism – Pathogenicity

Footnotes

Authors’ address: Dong-Qing Wei, College of Life Science and Biotechnology, Shanghai Jiao Tong University, Shanghai, 200240, China

References

  1. Buck M, Bouguet-Bonnet S, Pastor RW, MacKerell AD., Jr Importance of the CMAP correction to the CHARMM22 protein force field: dynamics of hen lysozyme. Biophys J. 2006;90:L36–L38. doi: 10.1529/biophysj.105.078154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chou KC. A vectorized sequence-coupling model for predicting HIV protease cleavage sites in proteins. J Biol Chem. 1993;268:16938–16948. [PubMed] [Google Scholar]
  3. Chou KC. Review: prediction of HIV protease cleavage sites in proteins. Anal Biochem. 1996;233:1–14. doi: 10.1006/abio.1996.0001. [DOI] [PubMed] [Google Scholar]
  4. Chou KC. Insights from modelling the 3D structure of the extracellular domain of alpha7 nicotinic acetylcholine receptor. Biochem Biophys Res Commun. 2004a;319:433–438. doi: 10.1016/j.bbrc.2004.05.016. [DOI] [PubMed] [Google Scholar]
  5. Chou KC. Molecular therapeutic target for type-2 diabetes. J Proteome Res. 2004b;3:1284–1288. doi: 10.1021/pr049849v. [DOI] [PubMed] [Google Scholar]
  6. Chou KC. Review: structural bioinformatics and its impact to biomedical science. Curr Med Chem. 2004c;11:2105–2134. doi: 10.2174/0929867043364667. [DOI] [PubMed] [Google Scholar]
  7. Chou KC. Coupling interaction between thromboxane A2 receptor and alpha-13 subunit of guanine nucleotide-binding protein. J Proteome Res. 2005a;4:1681–1686. doi: 10.1021/pr050145a. [DOI] [PubMed] [Google Scholar]
  8. Chou KC. Modeling the tertiary structure of human cathepsin-E. Biochem Biophys Res Commun. 2005b;331:56–60. doi: 10.1016/j.bbrc.2005.03.123. [DOI] [PubMed] [Google Scholar]
  9. Chou KC, Carlacci L. Simulated annealing approach to the study of protein structures. Protein Eng. 1991;4:661–667. doi: 10.1093/protein/4.6.661. [DOI] [PubMed] [Google Scholar]
  10. Chou KC, Wei DQ, Du QS, Sirois S, Zhong WZ. Review: progress in computational approach to drug development against SARS. Curr Med Chem. 2006;13:3263–3270. doi: 10.2174/092986706778773077. [DOI] [PubMed] [Google Scholar]
  11. Chou KC, Wei DQ, Zhong WZ. Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochem Biophys Res Commun. 2003;308:148–151. doi: 10.1016/S0006-291X(03)01342-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Du QS, Sun H, Chou KC. Inhibitor design for SARS coronavirus main protease based on “distorted key theory”. Med Chem. 2007a;3:1–6. doi: 10.2174/157340607779317616. [DOI] [PubMed] [Google Scholar]
  13. Du QS, Wang S, Wei DQ, Sirois S, Chou KC. Molecular modelling and chemical modification for finding peptide inhibitor against SARS CoV Mpro. Anal Biochem. 2005;337:262–270. doi: 10.1016/j.ab.2004.10.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Du QS, Wang SQ, Chou KC. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus. Biochem Biophys Res Commun. 2007b;362:525–531. doi: 10.1016/j.bbrc.2007.08.025. [DOI] [PubMed] [Google Scholar]
  15. Du QS, Wang SQ, Wei DQ, Zhu Y, Guo H, Sirois S, Chou KC. Polyprotein cleavage mechanism of SARS CoV Mpro and chemical modification of octapeptide. Peptides. 2004;25:1857–1864. doi: 10.1016/j.peptides.2004.06.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hatta M, Gao P, Halfmann P, Kawaoka Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science. 2001;293:1840–1842. doi: 10.1126/science.1062882. [DOI] [PubMed] [Google Scholar]
  17. Henrich S, Cameron A, Bourenkov GP, Kiefersauer R, Huber R, Lindberg I, Bode W, Than ME. The crystal structure of the proprotein processing proteinase furin explains its stringent specificity. Nat Struct Biol. 2003;10:520–526. doi: 10.1038/nsb941. [DOI] [PubMed] [Google Scholar]
  18. Henrich S, Lindberg I, Bode W, Than ME. Proprotein convertase models based on the crystal structures of furin and kexin: explanation of their specificity. J Mol Biol. 2005;345:211–227. doi: 10.1016/j.jmb.2004.10.050. [DOI] [PubMed] [Google Scholar]
  19. Holyoak T, Kettner CA, Petsko GA, Fuller RS, Ringe D. Structural basis for differences in substrate selectivity in Kex2 and furin protein convertases. Biochemistry. 2004;43:2412–2421. doi: 10.1021/bi035849h. [DOI] [PubMed] [Google Scholar]
  20. Ibrahim BS, Shamaladevi N, Pattabhi V. Trypsin activity reduced by an autocatalytically produced nonapeptide. J Biomol Struct Dyn. 2004;21:737–744. doi: 10.1080/07391102.2004.10506964. [DOI] [PubMed] [Google Scholar]
  21. Kawaoka Y, Webster RG. Sequence requirements for cleavage activation of influenza virus hemagglutinin expressed in mammalian cells. Proc Natl Acad Sci USA. 1988;85:324–328. doi: 10.1073/pnas.85.2.324. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kido H, Sakai K, Kishino Y, Tashiro M. Pulmonary surfactant is a potential endogenous inhibitor of proteolytic activation of Sendai virus and influenza A virus. FEBS Lett. 1993;322:115–119. doi: 10.1016/0014-5793(93)81549-F. [DOI] [PubMed] [Google Scholar]
  23. Krysan DJ, Rockwell NC, Fuller RS. Quantitative characterization of furin specificity. Energetics of substrate discrimination using an internally consistent set of hexapeptidyl methylcoumarinamides. J Biol Chem. 1999;274:23229–23234. doi: 10.1074/jbc.274.33.23229. [DOI] [PubMed] [Google Scholar]
  24. Ma W, Tang C, Lai L. Specificity of trypsin and chymotrypsin: loop-motion-controlled dynamic correlation as a determinant. Biophys J. 2005;89:1183–1193. doi: 10.1529/biophysj.104.057158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Martin J, Wharton SA, Lin YP, Takemoto DK, Skehel JJ, Wiley DC, Steinhauer DA. Studies of the binding properties of influenza hemagglutinin receptor-site mutants. Virology. 1998;241:101–111. doi: 10.1006/viro.1997.8958. [DOI] [PubMed] [Google Scholar]
  26. Morris GM, Goodsell DS, Huey R, Olson AJ. Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J Comput Aided Mol Des. 1996;10:293–304. doi: 10.1007/BF00124499. [DOI] [PubMed] [Google Scholar]
  27. Radisky ES, Lee JM, Lu CJ, Koshland DE., Jr Insights into the serine protease mechanism from atomic resolution structures of trypsin reaction intermediates. Proc Natl Acad Sci USA. 2006;103:6835–6840. doi: 10.1073/pnas.0601910103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Rozan L, Krysan DJ, Rockwell NC, Fuller RS. Plasticity of extended subsites facilitates divergent substrate recognition by Kex2 and furin. J Biol Chem. 2004;279:35656–35663. doi: 10.1074/jbc.M405362200. [DOI] [PubMed] [Google Scholar]
  29. Schechter I, Berger A. On the size of the active site in protease. I. Papain. Biochem Biophys Res Commun. 1967;27:157–162. doi: 10.1016/S0006-291X(67)80055-X. [DOI] [PubMed] [Google Scholar]
  30. Schmidt A, Jelsch C, Ostergaard P, Rypniewski W, Lamzin VS. Trypsin revisited: crystallography AT (SUB) atomic resolution and quantum chemistry revealing details of catalysis. J Biol Chem. 2003;278:43357–43362. doi: 10.1074/jbc.M306944200. [DOI] [PubMed] [Google Scholar]
  31. Sirois S, Wei DQ, Du QS, Chou KC. Virtual screening for SARS-CoV protease based on KZ7088 pharmacophore points. J Chem Inf Comput Sci. 2004;44:1111–1122. doi: 10.1021/ci034270n. [DOI] [PubMed] [Google Scholar]
  32. Steinhauer DA. Role of hemagglutinin cleavage for the pathogenicity of influenza virus. Virology. 1999;258:1–20. doi: 10.1006/viro.1999.9716. [DOI] [PubMed] [Google Scholar]
  33. Stevens J, Blixt O, Tumpey TM, Taubenberger JK, Paulson JC, Wilson IA. Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science. 2006;312:404–410. doi: 10.1126/science.1124513. [DOI] [PubMed] [Google Scholar]
  34. Wang JF, Wei DQ, Li L, Zheng SY, Li YX, Chou KC. 3D structure modeling of cytochrome P450 2C19 and its implication for personalized drug design. Biochem Biophys Res Commun. 2007a;355:513–519. doi: 10.1016/j.bbrc.2007.01.185. [DOI] [PubMed] [Google Scholar]
  35. Wang SQ, Du QS, Chou KC. Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases. Biochem Biophys Res Commun. 2007b;354:634–640. doi: 10.1016/j.bbrc.2006.12.235. [DOI] [PubMed] [Google Scholar]
  36. Wang SQ, Du QS, Zhao K, Li AX, Wei DQ, Chou KC. Virtual screening for finding natural inhibitor against cathepsin-L for SARS therapy. Amino Acids. 2007c;33:129–135. doi: 10.1007/s00726-006-0403-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Wei DQ, Du QS, Sun H, Chou KC. Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands. Biochem Biophys Res Commun. 2006a;344:1048–1055. doi: 10.1016/j.bbrc.2006.03.210. [DOI] [PubMed] [Google Scholar]
  38. Wei DQ, Sirois S, Du QS, Arias HR, Chou KC. Theoretical studies of Alzheimer’s disease drug candidate [(2,4-dimethoxy) benzylidene]-anabaseine dihydrochloride (GTS-21) and its derivatives. Biochem Biophys Res Commun. 2005;338:1059–1064. doi: 10.1016/j.bbrc.2005.10.047. [DOI] [PubMed] [Google Scholar]
  39. Wei DQ, Zhang R, Du QS, Gao WN, Li Y, Gao H, Wang SQ, Zhang X, Li AX, Sirois S, Chou KC. Anti-SARS drug screening by molecular docking. Amino Acids. 2006b;31:73–80. doi: 10.1007/s00726-006-0361-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Wei H, Zhang R, Wang C, Zheng H, Chou KC, Wei DQ. Molecular insights of SAH enzyme catalysis and their implication for inhibitor design. J Theor Biol. 2007;244:692–702. doi: 10.1016/j.jtbi.2006.09.011. [DOI] [PubMed] [Google Scholar]
  41. Wheatley JL, Holyoak T. Differential P1 arginine and lysine recognition in the prototypical proprotein convertase Kex2. Proc Natl Acad Sci USA. 2007;104:6626–6631. doi: 10.1073/pnas.0701983104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Wiley DC, Skehel JJ. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem. 1987;56:365–394. doi: 10.1146/annurev.bi.56.070187.002053. [DOI] [PubMed] [Google Scholar]
  43. Zhang R, Wei DQ, Du QS, Chou KC. Molecular modeling studies of peptide drug candidates against SARS. Med Chem. 2006;2:309–314. doi: 10.2174/157340606776930736. [DOI] [PubMed] [Google Scholar]

Articles from Amino Acids are provided here courtesy of Nature Publishing Group

RESOURCES